Rocket Pharmaceuticals/$RCKT

1D1W1MYTD1Y5YMAX

About Rocket Pharmaceuticals

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Ticker
$RCKT
Sector
Health
Primary listing
NASDAQ
Employees
202
Headquarters
Cranbury, United States
Website
www.rocketpharma.com

RCKT Metrics

BasicAdvanced
$368M
-
-$0.15
0.47
-

What the Analysts think about RCKT

Analyst ratings (Buy, Hold, Sell) for Rocket Pharmaceuticals stock.
Analyst projections of the future price of Rocket Pharmaceuticals stock.

Bulls say / Bears say

On March 27 2026, the FDA granted accelerated approval for KRESLADI™ (marnetegragene autotemcel) to treat severe LAD-I in pediatric patients, marking Rocket’s first commercial gene therapy and awarding it a Rare Pediatric Disease Priority Review Voucher. (Reuters)
In June 2026, the U.S. FDA lifted the clinical hold on the pivotal Phase 2 trial of RP-A501 for Danon disease after safety re-evaluation, allowing dosing to resume under a revised protocol and advancing the cardiovascular AAV program. (Reuters via Investing.com)
Following the $180 million sale of its Priority Review Voucher in June 2026, Rocket’s pro forma cash balance rose to approximately $322.6 million, extending its operational runway into Q2 2028 to fund ongoing R&D. (Investing.com)
In July 2026, Rocket withdrew its U.S. Biologics License Application for RP-L102 in Fanconi anemia, signaling a deprioritization and potential setback for a once-key pipeline program. (Reuters)
Despite FDA approval, analysts warn KRESLADI’s commercial potential is constrained by its ultra-rare indication and the company’s planned “minimum viable launch strategy,” limiting meaningful revenue upside. (Reuters)
Analysts forecast Rocket will report a net loss of $0.41 per share in its upcoming quarter, underscoring continued cash burn and the likelihood of further funding or dilution. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 6 Sept 2026.

RCKT Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

RCKT Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

RCKT News

AllArticlesVideos

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

Business Wire1 month ago

Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial

Benzinga1 month ago

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

Business Wire1 month ago

Funds containing RCKT

AllUSDGBPEUR
Funds
Fund name
Fund size
$RCKT weighting
iShares Nasdaq US Biotechnology$BTEC
$1.2B0.02%
iShares Nasdaq US Biotechnology£BTEK
£865M0.02%
SPDR Russell 2000 US Small Cap€R2US
€4.8B0.01%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.